Arsenic trioxide
-
Subject Areas on Research
- A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
- A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
- A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).
- Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
- Arsenic trioxide uptake by human and rat aquaglyceroporins.
- Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
- Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
- Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
- Interlaboratory validation of a new assay for DNA-protein crosslinks.
- Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series.
- Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
- Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
- Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.